guaifenesin has been researched along with Sleep Apnea, Obstructive in 4 studies
Guaifenesin: An expectorant that also has some muscle relaxing action. It is used in many cough preparations.
Sleep Apnea, Obstructive: A disorder characterized by recurrent apneas during sleep despite persistent respiratory efforts. It is due to upper airway obstruction. The respiratory pauses may induce HYPERCAPNIA or HYPOXIA. Cardiac arrhythmias and elevation of systemic and pulmonary arterial pressures may occur. Frequent partial arousals occur throughout sleep, resulting in relative SLEEP DEPRIVATION and daytime tiredness. Associated conditions include OBESITY; ACROMEGALY; MYXEDEMA; micrognathia; MYOTONIC DYSTROPHY; adenotonsilar dystrophy; and NEUROMUSCULAR DISEASES. (From Adams et al., Principles of Neurology, 6th ed, p395)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Raff, H | 1 |
| Ettema, SL | 1 |
| Eastwood, DC | 1 |
| Woodson, BT | 1 |
| Wan, N | 1 |
| Tang, X | 1 |
| Ding, H | 1 |
| Yan, Y | 1 |
| Zhuang, Y | 1 |
| Qi, C | 1 |
| Chen, Q | 1 |
| Xie, W | 1 |
| Zhang, J | 1 |
| Wang, Y | 1 |
| Liang, M | 1 |
| Ning, W | 1 |
| Cao, J | 1 |
| Winther, B | 1 |
| Gross, BC | 1 |
| Hendley, JO | 1 |
| Early, SV | 1 |
| Schmidt, HJ | 1 |
| Bhandari, V | 1 |
| Bhandari, A | 1 |
| Davies, J | 1 |
| Marshall, BC | 1 |
| Praud, JP | 1 |
| Zar, HJ | 1 |
| Rubin, BK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Sleepiness and the Effects of CPAP on Salivary Cortisol and Alpha-Amylase Levels in Patients With Sleep Apnea[NCT01196117] | 18 participants (Actual) | Interventional | 2004-11-15 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Epworth Sleepiness Score (ESS) is a scale to assess sleepiness during waking hours. The scale ranges from 0-24 with higher scores indicative of greater sleepiness. (NCT01196117)
Timeframe: Difference between Baseline(Day 0) and Average of Day 1,7,14.
| Intervention | units on a scale (Median) |
|---|---|
| 14 Days of Placebo Therapy, Then CPAP | 10.7 |
| 14 Days of CPAP Therapy | 8.9 |
Salivary Cortisol was measured by enzyme-linked immunosorbent assay. The reference range for healthy adults is <4.2 nmol/l. (NCT01196117)
Timeframe: Day 7, 7am
| Intervention | nmol/l (Mean) |
|---|---|
| CPAP>= 3 Hours Per Night | 9.9 |
| CPAP<3 Hours Per Night | 13.3 |
Salivary Cortisol was measured by enzyme-linked immunosorbent assay. The reference range for healthy adults is <4.2 nmol/l. (NCT01196117)
Timeframe: Day 0, 11pm
| Intervention | nmol/l (Median) |
|---|---|
| CPAP>= 3 Hours Per Night | 3.2 |
| CPAP<3 Hours Per Night | 1.2 |
Salivary Cortisol was measured by enzyme-linked immunosorbent assay. The reference range for healthy adults is <4.2 nmol/l. (NCT01196117)
Timeframe: Day 1, 11pm
| Intervention | nmol/l (Median) |
|---|---|
| CPAP>= 3 Hours Per Night | 2.2 |
| CPAP<3 Hours Per Night | 1.8 |
Salivary Cortisol was measured by enzyme-linked immunosorbent assay. The reference range for healthy adults is <4.2 nmol/l. (NCT01196117)
Timeframe: Day 14, 11pm
| Intervention | nmol/l (Median) |
|---|---|
| CPAP>= 3 Hours Per Night | 1.9 |
| CPAP<3 Hours Per Night | 2.2 |
Salivary Cortisol was measured by enzyme-linked immunosorbent assay. The reference range for healthy adults is <4.2 nmol/l. (NCT01196117)
Timeframe: Day 7, 11pm
| Intervention | nmol/l (Median) |
|---|---|
| CPAP>= 3 Hours Per Night | 3.0 |
| CPAP<3 Hours Per Night | 2.5 |
Salivary Cortisol was measured by enzyme-linked immunosorbent assay. The reference range for healthy adults is <4.2 nmol/l. (NCT01196117)
Timeframe: Day 0, 7am
| Intervention | nmol/l (Median) |
|---|---|
| CPAP>= 3 Hours Per Night | 12.5 |
| CPAP<3 Hours Per Night | 12.1 |
Salivary Cortisol was measured by enzyme-linked immunosorbent assay. The reference range for healthy adults is <4.2 nmol/l. (NCT01196117)
Timeframe: Day 1, 7am
| Intervention | nmol/l (Median) |
|---|---|
| CPAP>= 3 Hours Per Night | 7.4 |
| CPAP<3 Hours Per Night | 13.6 |
Salivary Cortisol was measured by enzyme-linked immunosorbent assay. The reference range for healthy adults is <4.2 nmol/l. (NCT01196117)
Timeframe: Day 14, 7am
| Intervention | nmol/l (Median) |
|---|---|
| CPAP>= 3 Hours Per Night | 9.2 |
| CPAP<3 Hours Per Night | 15.0 |
1 review available for guaifenesin and Sleep Apnea, Obstructive
| Article | Year |
|---|---|
The future in paediatric respirology.
Topics: Adult; Asthma; Bronchopulmonary Dysplasia; Child; Chronic Disease; Cystic Fibrosis; Humans; Infant, | 2010 |
1 trial available for guaifenesin and Sleep Apnea, Obstructive
| Article | Year |
|---|---|
Salivary cortisol in obstructive sleep apnea: the effect of CPAP.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Continuous Positive Airway Pressure; Expecto | 2011 |
2 other studies available for guaifenesin and Sleep Apnea, Obstructive
| Article | Year |
|---|---|
Influence of coexistence of mild OSA on airway mucus hypersecretion in patients with COPD.
Topics: Breath Tests; Epithelial Cells; Humans; Mucus; Pulmonary Disease, Chronic Obstructive; Sleep Apnea, | 2021 |
Location of bacterial biofilm in the mucus overlying the adenoid by light microscopy.
Topics: Adenoids; Bacteria; Biofilms; Child; Chronic Disease; Coloring Agents; Humans; In Situ Hybridization | 2009 |